## Zuschriften

## Natural Product Synthesis

## An Efficient Total Synthesis of Optically Active Tetrodotoxin\*\*

Toshio Nishikawa, Daisuke Urabe, and Minoru Isobe\*

Tetrodotoxin (TTX, 1), a toxic principle of puffer-fish poison, is one of the most famous natural products because of its novel structure coupled with its potent biological activity.<sup>[1]</sup> The structure was revealed by Hirata, Goto, and co-workers,

[\*] Dr. T. Nishikawa, D. Urabe, Prof. M. Isobe Graduate School of Bioagricultural Sciences Nagoya University

Chikusa, Nagoya 464-8601 (Japan)

Fax: (+81) 52-789-4111

E-mail: isobem@agr.nagoya-u.ac.jp

Dr. T. Nishikawa

PRESTO, Japan Science and Technology Agency (JST) 4-1-8 Honcho, Kawaguchi, Saitama, 332-0012 (Japan)

[\*\*] This work was supported financially by a Grand-in-Aid for Scientific Research and the 21st Century COE grant from MEXT, PRESTO of the Japan Science and Technology Agency (JST), and the Naito Foundation. We thank Dr. Masanori Asai for carrying out some  $preliminary\ experiments.$ 



Supporting information for this article is available on the WWW under http://www.angewandte.org or from the author.

Tsuda et al., and Woodward in the 1960s<sup>[2]</sup> to be an unprecedented multifunctional structure that includes a polyhydroxylated dioxaadamantane unit with an ortho ester and a cyclic guanidine unit with a hemiaminal. The discovery that this toxin acts as a specific blocker of voltage-dependent sodium channels has led to its widespread use as a biochemical tool in neurophysiology.<sup>[3]</sup> The highly functionalized cage structure and unusual chemical properties of (-)-tetrodotoxin (1) had hindered efforts towards its synthesis<sup>[4]</sup> until our recent total synthesis, [5] although Kishi and co-workers had already reported the total synthesis of racemic tetrodotoxin in 1972. [6] Another total synthesis of **1** was reported by Hinman and Du Bois in 2003.<sup>[7]</sup> Over the last few decades, a variety of analogues of tetrodotoxin, such as 11-deoxytetrodotoxin (2), 5,6,11-trideoxytetrodotoxin, and chiriquitoxin (4), have been isolated not only from puffer fish, but from many other organisms living in oceanic and fresh water, as well as from

Scheme 1. Reagents and conditions: a) TESOTf, pyridine, CH<sub>3</sub>CN, room temperature; b) SeO<sub>2</sub>, PNO, dioxane, reflux; c) NaBH<sub>4</sub>, CeCl<sub>3</sub>·7 H<sub>2</sub>O, MeOH, 0°C; d) TESOTf, 2,6-lutidine, CH<sub>2</sub>Cl<sub>2</sub>, 0°C; e) MCPBA, Na<sub>2</sub>HPO<sub>4</sub>, CH<sub>2</sub>Cl<sub>2</sub>, room temperature; f) O<sub>3</sub>, CH<sub>2</sub>Cl<sub>2</sub>, -78°C, then Et<sub>3</sub>N; g) TMS-C=CH, EtMgBr, THF, 0°C; h) Ac<sub>2</sub>O, DMAP, pyridine, room temperature; i) TBAF, THF, -10°C. TBAF = tetrabutylammonium fluoride, DMAP = 4-dimethylaminopyridine, TES = triethylsilyl, Tf=trifluoromethanesulfonyl, TMS=trimethylsilyl.

terrestrial animals.<sup>[8]</sup> These new findings have raised several interesting issues, such as questions about the biosynthesis of tetrodotoxin and the organisms that produce it,<sup>[9]</sup> as well as about the resistance mechanism and the actual biological function of tetrodotoxin in puffer fish.<sup>[10,11]</sup> During the course of our synthetic studies on tetrodotoxin with the aim of analyzing such problems, we have reported the total synthesis of several naturally occurring and nonnatural tetrodotoxin analogues, such as 5,11-dideoxytetrodotoxin,<sup>[12]</sup> 11-deoxytetrodotoxin (2),<sup>[13]</sup> and 8,11-dideoxytetrodotoxin (3),<sup>[14]</sup> from a common synthetic intermediate 6 (Scheme 1).<sup>[15]</sup> We describe herein an efficient total synthesis of (—)-tetrodotoxin (1) on the basis of an alternative strategy to that used for the first total synthesis of 1 in our laboratory.<sup>[5]</sup>

The synthesis commenced with the hydroxylation of the vinylic methyl group of an intermediate 8 in our synthesis of 11-deoxytetrodotoxin.[13] This intermediate was prepared in 17 steps from the chiral starting material levoglucosenone (5) through the common intermediate  $\mathbf{6}^{[15]}$  and an intermediate  $\mathbf{7}$ for 5,11-dideoxytetrodotoxin<sup>[12]</sup> (Scheme 1). Following protection of the diol as the bis(triethylsilyl) ether 9, the allylic oxidation of 9 was carried out with selenium dioxide and pyridine N-oxide (PNO)[16] to give the corresponding unsaturated aldehyde, which was reduced under the Luche conditions to the allylic alcohol 10 in moderate overall yield. The protection of the resulting primary alcohol with a TES group was followed by treatment with m-chloroperbenzoic acid (MCPBA) to afford a single epoxide 11 in high yield. In analogy with the previous syntheses of tetrodotoxin analogues,[12-14] the vinyl group was cleaved by ozonolysis followed by in situ reduction with Et<sub>3</sub>N to yield the aldehyde 12, which was subjected to the stereoselective addition of acetylide as a carboxylic acid equivalent. In this case, the alkynyl magnesium bromide prepared from (trimethylsilyl)acetylene and EtMgBr in THF was found to be the best reagent, and these conditions led to a 4:1 mixture of 13 from

**Scheme 2.** Reagents and conditions: a) KMnO<sub>4</sub>, NaIO<sub>4</sub>, NaHCO<sub>3</sub>, tBuOH,  $H_2O$ ,  $50\,^{\circ}C$ ; b)  $H_2O_2$  (30%), NaHCO<sub>3</sub>, MeOH, room temperature; c) TESOTf, 2,6-lutidine,  $CH_2CI_2$ ,  $-40\,^{\circ}C$ ; d) Ac<sub>2</sub>O, pyridine, room temperature.

## Zuschriften

which the desired product was isolated in 70 % yield. <sup>[17]</sup> The major product **13** was transformed by acetylation and removal of the TMS group into the propargyl acetate **14**, which was set for oxidative cleavage of the acetylenic moiety.

The attempted cleavage of the acetylenic moiety of 14 with ruthenium oxide, which had been employed in our previous syntheses of deoxytetrodotoxin analogues, failed to give the expected  $\alpha$ -acetoxycarboxylic acid or lactone. The product obtained was instead found to be the  $\alpha$ -keto acid 15,  $^{[18]}$  thus indicating steric congestion around the acetylenic moiety. Further experiments led us to find that KMnO4 and NaIO4 were the most efficient oxidants  $^{[19]}$  of 14 to the  $\alpha$ -keto acid 15, which was cleaved with alkaline hydrogen peroxide to furnish a mixture of the desired lactone 18 and a partially desilylated product 17 (Scheme 2). The treatment of the crude

reaction mixture with TESOTf and 2,6-lutidine effected resilvation to give **18**. Acetylation of the hydroxy group at C9 gave **19**, which contains a fully functionalized cyclohexane ring with the correct stereochemistry.

The remaining tasks in the total synthesis of tetrodotoxin were the cleavage of the 1,2-diol protected as an acetonide and the installation of the guanidine functionality. Major difficulties encountered at this stage were epimerization at C9 and the low nucleophilicity of the amino group obtained from the trichloroacetamide. After extensive investigations of protective-group strategies for hydroxy groups, we eventually found the following successful route via the key intermediate 23, which contains an acetal and an ortho ester (Scheme 3). Thus, prior to cleavage of the acetonide with periodic acid, it was necessary to exchange the acid-sensitive TES protective groups for acetate groups. The removal of all TES groups in 19 with TBAF was followed by peracetylation to give pentaacetate 20[20] in the form of an ortho ester. [21] Attempted desilvlation of 18 (with a free 9-hydroxy group) under the same conditions resulted in exclusive deprotection of the

**Scheme 3.** Reagents and conditions: a) TBAF, CH<sub>3</sub>CN, 0°C; b) Ac<sub>2</sub>O, pyridine, room temperature; c) HIO<sub>4</sub>, AcOMe, room temperature; d) CSA, HC(OMe)<sub>3</sub>, MeOH, room temperature; e) aqueous NH<sub>3</sub>, MeOH, 0°C; f) TBSOTf, 2,6-lutidine, CH<sub>2</sub>Cl<sub>2</sub>, 0°C. CSA = camphor sulfonic acid, TBS = tert-butyldimethylsilyl.

11-hydroxy group without epimerization, thus indicating that the presence of the acetate group on the 9-hydroxy group might be crucial for deprotection of TES groups at the 7- and 8-positions. The 1,2-acetonide was cleaved with periodic acid to give an aldehyde, which was immediately protected as the dimethylacetal **21**. Reductive cleavage of the trichloroacetamide with DIBAL-H<sup>[14,22]</sup> required protection of the ortho ester with a silyl group. Fortunately, we found that the treatment of **21** with aqueous ammonia in MeOH afforded **22** exclusively. Compound **22** was treated with an excess of TBSOTf to give a 6:1 inseparable mixture of the acetal **23**.<sup>[21,23]</sup>

All acyl protecting groups in **23** were removed with DIBAL-H at -40 °C for 8 h (Scheme 4). <sup>[24]</sup> The resulting amine **24** was then guanidinylated with bis(Boc-(S)-methyl-

**Scheme 4.** Reagents and conditions: a) DIBAL-H,  $CH_2CI_2$ , -40°C; b) BocN= C(SMe)NHBoc,  $HgCI_2$ ,  $Et_3N$ , DMF, room temperature; c) TFA,  $H_2O$ , room temperature. Boc=*tert*-butoxycarbonyl, DIBAL-H=diisobutylaluminum hydride, DMF=N,N-dimethylformamide, TFA=trifluoroacetic acid.

isothiourea) in the presence of mercuric chloride<sup>[25]</sup> to give **25**, a suitably protected precursor of tetrodotoxin. Exposure of **25** to aqueous TFA caused global deprotection and subsequent formation of the cyclic guanidine moiety to furnish tetrodotoxin (**1**) and 4,9-anhydrotetrodotoxin (**26**) in 36 and 58% yield, respectively, after purification by HPLC on an ion-exchange resin. The synthetic material **1** proved to be identical in all respects to natural tetrodotoxin.

In summary, the total synthesis of tetrodotoxin from 8 has been accomplished in a highly concise manner, which should enable us to supply a variety of tetrodotoxin derivatives that are not readily accessible from natural products for biochemical studies.

Received: April 12, 2004

**Keywords:** guanidine  $\cdot$  ion channels  $\cdot$  natural products  $\cdot$  tetrodotoxin  $\cdot$  total synthesis

- [1] For a review, see: "Tetrodotoxin, Saxitoxin, and the Molecular Biology of the Sodium Channel" (Eds.: C. Y. Kao, S. Lovinson), *Ann. N. Y. Acad. Sci.* **1986**, 479.
- [2] a) T. Goto, Y. Kishi, S. Takahashi, Y. Hirata, *Tetrahedron* 1965, 21, 2059–2088; b) K. Tsuda, S. Ikuma, M. Kawamura, R. Tachikawa, K. Sakai, C. Tamura, O. Amakasu, *Chem. Pharm. Bull.* 1964, 12, 1357–1374; c) R. B. Woodward, *Pure. Appl. Chem.* 1964, 9, 49–74.
- [3] a) T. Narahashi, J. W. Moore, W. R. Scott, J. Gen. Physiol. 1964, 47, 965–974; b) F. Hucho, Angew. Chem. 1994, 106, 23; Angew. Chem. Int. Ed. Engl. 1995, 34, 39–50.
- [4] For leading references, see: a) Y. Ohtani, T. Shinada, Y. Ohfune, Synlett 2003, 619-622; b) T. Itoh, M. Watanabe, T. Fukuyama, Synlett 2002, 1323-1325; c) B. Noya, M. D. Paredes, L. Ozores, R. Alonso, J. Org. Chem. 2000, 65, 5960-5968; d) B. Fraser-Reid, C. S. Burgey, R. Vollerthun, Pure Appl. Chem. 1998, 70, 285-288; e) K. Sato, Y. Kajihara, Y. Nakamura, J. Yoshimura, Chem. Lett. 1991, 1559-1562; f) R. J. Nachman, M. Hönel, T. M. Williams, R. C. Halaska, H. S. Mosher, J. Org. Chem. 1986, 51, 4802-4806; g) J. F. W. Keana, J. S. Bland, P. J. Boyle, M. Erion, R. Hartling, J. R. Husman, R. B. Roman, J. Org. Chem. 1983, 48, 3621-3627; J. F. W. Keana, J. S. Bland, P. J. Boyle, M. Erion, R. Hartling, J. R. Husman, R. B. Roman, J. Org. Chem. 1983, 48, 3627-3631.
- [5] N. Ohyabu, T. Nishikawa, M. Isobe, J. Am. Chem. Soc. 2003, 125, 8798–8805.
- [6] a) Y. Kishi, M. Aratani, T. Fukuyama, F. Nakatsubo, T. Goto, S. Inoue, H. Tanino, S. Sugiura, H. Kakoi, J. Am. Chem. Soc. 1972, 94, 9217–9219; b) Y. Kishi, T. Fukuyama, M. Aratani, F. Nakatsubo, T. Goto, S. Inoue, H. Tanino, S. Sugiura, H. Kakoi, J. Am. Chem. Soc. 1972, 94, 9219–9221.
- [7] A. Hinman, J. Du Bois, J. Am. Chem. Soc. 2003, 125, 11510– 11511.
- [8] a) M. Yotsu-Yamashita, J. Toxicol. Toxin Rev. 2001, 20, 51-66;
   b) K. Miyazawa, T. Noguchi, J. Toxicol. Toxin Rev. 2001, 20, 11-33
- [9] The biosynthetic precursors and pathway are completely unknown, whereas tetrodotoxin-producing bacteria have been identified; see: a) T. Yasumoto, D. Yamamura, M. Yotsu, T. Michishita, A. Endo, Y. Kotaki, Agric. Biol. Chem. 1986, 50, 793-795; b) T. Noguchi, J.-K. Jeon, O. Arakawa, H. Sugita, Y. Deguchi, Y. Shida, K. Hashimoto, J. Biochem. 1986, 99, 311-314; c) Y. Shimizu, Ann. N. Y. Acad. Sci. 1986, 479, 24-31.
- [10] a) T. Matsui, K. Yamamori, K. Furukawa, M. Kono, *Toxicon* **2000**, *38*, 463–468; b) M. Yotsu-Yamashita, A. Sugimoto, T. Terakawa, Y. Shoji, T. Miyazawa, T. Yasumoto, *Eur. J. Biochem.* **2001**, *268*, 5937–5946.
- [11] K. Matsumura, Nature 1995, 378, 563-564.
- [12] a) T. Nishikawa, M. Asai, N. Ohyabu, N. Yamamoto, M. Isobe,
   Angew. Chem. 1999, 111, 3268-3271; Angew. Chem. Int. Ed.
   1999, 38, 3081-3084; b) M. Asai, T. Nishikawa, N. Ohyabu, N. Yamamoto, M. Isobe, Tetrahedron 2001, 57, 4543-4558.
- [13] T. Nishikawa, M. Asai, M. Isobe, J. Am. Chem. Soc. 2002, 124, 7847–7852.
- [14] a) T. Nishikawa, D. Urabe, K. Yoshida, T. Iwabuchi, M. Asai, M. Isobe, *Org. Lett.* **2002**, *4*, 2679–2682; b) T. Nishikawa, D. Urabe, K. Yoshida, T. Iwabuchi, M. Asai, M. Isobe, *Chem. Eur. J.* **2004**, *10*, 452–462.
- [15] T. Nishikawa, M. Asai, N. Ohyabu, N. Yamamoto, Y. Fukuda, M. Isobe, *Tetrahedron* 2001, 57, 3875 3883.
- [16] K. A. Parker, A. Dermatakis, J. Org. Chem. 1997, 62, 6692–6696.
- [17] The configuration of the major product could not be determined at this stage.
- [18] The structure was confirmed by the methylation of **15** with TMS-CHN<sub>2</sub>.

- [19] P. A. Grieco, D. L. Flynn, R. E. Zelle, J. Am. Chem. Soc. 1984, 106, 6414-6417.
- [20] The configuration at C9 was established based on the long-range coupling  $(J=1~{\rm Hz})$  between 9-H and 4a-H.
- [21] The structure of the ortho ester was confirmed by  $^{13}$ C NMR spectroscopy;  $\delta = 108.2$  ppm for compound **20**,  $\delta = 108.5$  ppm for compound **23**.
- [22] T. Oishi, K. Ando, K. Inomoya, H. Sato, M. Iida, N. Chida, Org. Lett. 2002, 4, 151–154.
- [23] The configuration of the acetal was determined as shown in Scheme 3 based on the coupling constant for 4-H and 4a-H; see reference [13].
- [24] The temperature was important for obtaining the amine in good yield. At an elevated temperature (around 0 °C) the product was obtained in very low yield.
- [25] a) K. S. Kim, L. Qian, Tetrahedron Lett. 1993, 34, 7677 7680;
  b) R. J. Bergeron, J. S. McManis, J. Org. Chem. 1987, 52, 1700 1703.